Đang chuẩn bị liên kết để tải về tài liệu:
Comparing stereotactic ablative radiotherapy (SABR) versus re-trans-catheter arterial chemoembolization (re-TACE) for hepatocellular carcinoma patients who had incomplete response after initial TACE (TASABR): A randomized controlled trial

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Hepatocellular carcinoma (HCC) accounts for 75–85% of primary liver cancers and is prevalent in the Asia-Pacific region. Till now, trans-arterial chemoembolization (TACE) is still one of common modalities in managing unresectable intermediate-stage HCC. | Comparing stereotactic ablative radiotherapy SABR versus re-trans-catheter arterial chemoembolization re-TACE for hepatocellular carcinoma patients who had incomplete response after initial TACE TASABR A randomized controlled trial

TÀI LIỆU LIÊN QUAN

Comparing stereotactic ablative radiotherapy (SABR) versus re-trans-catheter arterial chemoembolization (re-TACE) for hepatocellular carcinoma patients who had incomplete response after initial TACE (TASABR): A randomized controlled trial

Comparing conVEntional RadioTherapy with stereotactIC body radiotherapy in patients with spinAL metastases: Study protocol for an randomized controlled trial following the cohort multiple randomized controlled trial design